UC PRO.AKT.ANL. 11/24 BAYN/ DE000HC6UP31 /
2024-07-25 9:45:25 AM | Chg.+0.230 | Bid11:37:38 AM | Ask11:37:38 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
59.770EUR | +0.39% | 60.220 Bid Size: 500,000 |
60.240 Ask Size: 500,000 |
BAYER AG NA O.N. | 47.50 - | 2024-11-22 | Call |
GlobeNewswire
05-30
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
05-30
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
05-28
Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
GlobeNewswire
05-02
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
04-18
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
04-16
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
04-11
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
03-25
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
03-06
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
03-04
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
02-15
2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
GlobeNewswire
02-13
Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire
02-13
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
GlobeNewswire
01-05
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)